| Title |
Targeting persistent androgen receptor signaling in castration-resistant prostate cancer
|
|---|---|
| Published in |
Medical Oncology, April 2016
|
| DOI | 10.1007/s12032-016-0759-3 |
| Pubmed ID | |
| Authors |
Laura Graham, Michael T. Schweizer |
| Abstract |
Castration-resistant prostate cancer (CRPC), the invariably lethal phenotype of advanced prostate cancer, represents a clinical state defined by disease progression despite reduction of testosterone to castrate levels (i.e., ≤50 ng/dL). Although resistant to androgen-deprivation therapy (i.e., LHRH agonists/antagonists), CRPC continues to depend on the androgen receptor (AR)-signaling pathway. Supporting the importance of AR-signaling in a castration-resistant state, the next-generation AR-signaling inhibitors enzalutamide and abiraterone have been shown to afford a survival benefit in men with metastatic CRPC. However, primary and secondary resistance mechanisms to these agents inevitably drive continued disease progression-often as a result of re-activation of AR-signaling. With increased understanding of the mechanisms underlying how continued AR-signaling occurs in spite of drugs like abiraterone and enzalutamide, a new wave of therapies is emerging designed to more effectively target AR-signaling. This review will focus on the more clinically relevant mechanisms of CRPC drug resistance and our ongoing efforts to develop drugs to target these mechanisms. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 1% |
| Germany | 1 | 1% |
| Unknown | 65 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 16 | 24% |
| Student > Ph. D. Student | 10 | 15% |
| Student > Bachelor | 8 | 12% |
| Student > Master | 7 | 10% |
| Student > Doctoral Student | 3 | 4% |
| Other | 8 | 12% |
| Unknown | 15 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 22% |
| Biochemistry, Genetics and Molecular Biology | 10 | 15% |
| Agricultural and Biological Sciences | 10 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
| Unspecified | 2 | 3% |
| Other | 5 | 7% |
| Unknown | 21 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 April 2016.
All research outputs
#18,450,346
of 22,860,626 outputs
Outputs from Medical Oncology
#797
of 1,295 outputs
Outputs of similar age
#219,947
of 300,377 outputs
Outputs of similar age from Medical Oncology
#8
of 18 outputs
Altmetric has tracked 22,860,626 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,295 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 300,377 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.